Danish Multicenter Study of Adalimumab in Spondyloarthritis — DANISH  

Spondyloarthritis Clinical Trial

Official title: Can New Imaging- and Bio-markers Improve the Assessment of Disease Activity and Progression and Predict Therapeutic Outcome in Spondyloarthritis Patients Receiving Adalimumab

Status Active, not recruiting

Clinical Trial Summary

Spondyloarthropathies (SpA) are often diagnosed with a considerable delay (often 8-10 years from symptom onset), because the available clinical, biochemical and radiological methods are not sufficiently sensitive. TNF-a antagonists have recently been introduced for treatment of SpA, and current data indicate a higher efficacy than previously available therapies. The improved treatment options have increased the need for improved methods for diagnosis, monitoring and prognostication of these diseases, so that the efficient therapies can be initiated at the optimal time point and monitored optimally. Magnetic resonance imaging (MRI) and a number of biomarkers are promising, but not yet sufficiently studied, methods for this.

Clinical Trial Description

See brief summary ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Spondylarthritis
• Spondyloarthritis

• NCT number: NCT00477893
• Study type: Interventional
• Source: Glostrup University Hospital, Copenhagen
• Status: Active, not recruiting
• Phase: Phase 4
• Start date: February 2006
• Completion date: January 2013